Cargando…
Engineering nanoparticles to overcome barriers to immunotherapy
Advances in immunotherapy have led to the development of a variety of promising therapeutics, including small molecules, proteins and peptides, monoclonal antibodies, and cellular therapies. Despite this wealth of new therapeutics, the efficacy of immunotherapy has been limited by challenges in targ...
Autores principales: | Toy, Randall, Roy, Krishnendu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689503/ https://www.ncbi.nlm.nih.gov/pubmed/29313006 http://dx.doi.org/10.1002/btm2.10005 |
Ejemplares similares
-
Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019) -
Immunotherapy biomarkers 2016: overcoming the barriers
por: Gulley, James L., et al.
Publicado: (2017) -
Overcoming delivery barriers in immunotherapy for glioblastoma
por: Rui, Yuan, et al.
Publicado: (2021) -
Barriers to overcoming immunotherapy resistance in glioblastoma
por: Gillette, Julia S., et al.
Publicado: (2023) -
Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers
por: Lechpammer, Mirna, et al.
Publicado: (2022)